Stockholders' Equity (Details) - USD ($)		3 Months Ended			6 Months Ended
	Apr. 03, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Apr. 17, 2017	Dec. 31, 2016	Jan. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of preferred share purchase rights for each outstanding share of common stock							1
Common stock, par value (in dollars per share)		$ 0.01			$ 0.01		$ 0.01	$ 0.01
Preferred stock, par value (in dollars per share)		0.01			0.01		0.01	$ 0.01
Initial exercise price (in usd per share)		$ 34.12			$ 34.12		$ 80
Number of preferred share, called by each right (in shares)		0.001			0.001
Preferred stock, economic equivalent to common stock (in shares)					1,000
Period following public announcement of an acquiring person (in days)					10 days
Period following intention of a tender offer (in days)					10 days
Covenant, consolidated assets sold (as a percent)					50.00%
Share repurchase program, authorized amount									$ 60,000,000.0
Common stock repurchased and retired (in shares)			0		831,744
Stock repurchased and retired during period, value					$ 20,000,000
Average share price (in usd per share)					$ 24.05
Increase in total stockholders' equity					$ 13,100,000
Increase related to net shares issued in connection with the Endoceutics License Agreement					12,555,000	$ 0
Increase related to equity-based compensation expense					11,700,000
Net loss		$ (14,066,000)		$ (596,000)	(50,626,000)	$ (8,123,000)
Reduction related to changes in deferred taxes associated with debt		$ 27,200,000
Convertible Notes | Convertible Notes due 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase related to the Equity Component of debt					72,600,000
Debt issuance costs, allocated to equity component					2,200,000
Convertible Notes | Convertible Notes due 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reduction related to the Equity Component of debt repurchased					25,500,000
Endoceutics License Agreement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase related to net shares issued in connection with the Endoceutics License Agreement	$ 13,500,000				$ 13,500,000
Accounting Standards Update 2016-09, Excess Tax Benefit Component | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative- effect adjustment								$ 21,600,000
Common Stock
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Maximum majority ownership, resulting from 2017 net operating loss rights agreement (as a percent)					4.99%